Meeting
2024 ASCO Breakthrough
Utility of radiomic features in predicting clinical outcomes in stage II-III pancreatic cancer.
Authors
Haruka Itakura
Stanford University School of Medicine, Stanford, CA
Haruka Itakura , Qinmei Xu , Diego Toesca , Lucas Vitzthum , Arash Jamalian , Emil Schueler , Emel Alkim , J Richelcyn Baclay , Daniel Tandel Chang , George A. Fisher Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies
Sub Track
Omics for precision medicine
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 74)
DOI
10.1200/JCO.2024.42.23_suppl.74
Abstract #
74
Poster Bd #
E6
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Predicting rapid progression and overall survival in stage II-III pancreatic cancer using a CT-based radiomic signature.
First Author: Qinmei Xu
Poster
2024 ASCO Breakthrough
Clinical determinants of survival in patients with stage II-III pancreatic cancer.
First Author: Haruka Itakura
Poster
2024 ASCO Breakthrough
Analysis of prognostic factors in uterine cervical malignancy treated with concurrent chemoradiation therapy: A retrospective study in two centers in Korea.
First Author: Seung-Mi Lee
Poster
2024 ASCO Genitourinary Cancers Symposium
A novel radiomics-miRNAs integrated model to predict the histopathology of residual retroperitoneal masses in metastatic nonseminomatous germ cell tumors.
First Author: Xiangdong Li